Advertisement

U.S. Markets open in 1 hr 5 mins

S&P Futures
5,976.75
+18.50(+0.31%)
Dow Futures
43,980.00
+79.00(+0.18%)
Nasdaq Futures
20,998.00
+104.00(+0.50%)
Russell 2000 Futures
2,417.70
+11.90(+0.49%)
Crude Oil
71.39
-0.30(-0.42%)
Gold
2,684.90
+8.60(+0.32%)

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

0.7050

-0.0205

(-2.83%)

At close: 04:00PM EST

0.7000

-0.00

(-0.71%)

Pre-Market:

08:20AM EST

Trade prices are not sourced from all markets

All

GlobeNewswire
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancerPresentations include planned Phase 3 study design expanding use of Bria-IMT™ + CPI to any cancer patient with central nervous system (CNS) metastases PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company
Premium
MT Newswires
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
GlobeNewswire
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patientsMultiple outperforming patients with overall survival of over 2 yearsSurvival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhibitors (CPIs) and/or antibody-drug conjugates (ADCs) Final median overall survival calculation for the Phase 2 study is pending, as many patients